Prof. Gary Tse
Prof. Gary Tse matriculated at Trinity Hall, University of Cambridge in 2005 to read pre-clinical medicine. He subsequently completed his clinical training at Imperial College London, as well as PhD and MD from the University of Cambridge.
He is dually qualified in public health and pharmaceutical medicine, and is a medical examiner accredited by the Royal College of Pathologists. He is a Professor at the School of Nursing and Health Sciences, Hong Kong Metropolitan University (HKMU), where he served successively as the Associate Dean (Innovations and Research) and Head of Department of Population Health, and is currently the Deputy Director of the Exergaming Research Centre.
He is also a Distinguished Chair Professor at the Department of Cardiology, Second Hospital of Tianjin Medical University, China and a Visiting Professor at the Faculty of Health and Medical Sciences, University of Surrey. Prior to joining HKMU, Prof. Tse held a joint position as Clinical Reader at the University of Kent (with permanent appointment until retirement age) and Public Health Consultant at the Medway Council in local government, UK. He serves as a Nucleus Committee Member of the Population Health Section, European Association of Preventive Cardiology, for which he is the deputy representative for the Accreditation and Certification Subcommittees.
He is a Council Member, Secretary and President-Elect of the International Society of Electrocardiology, as well as a Member of the Board of Trustees of the International Society for Holter and Non-invasive Electrocardiology.
He is currently the Editor-in-Chief of Expert Opinion on Pharmacotherapy and Member of the World Health Organisation’s Technical Advisory Group for Diabetes. His strategic contributions to the World Health Organization and various international societies bridge the gap between pharmaceutical research and clinical practice. Through these roles, he directly informs the development of therapeutic protocols and the global regulation of medications for chronic disease management.
Dr Logan Manikam
Dr. Logan Manikam is a GMC-registered Consultant in Public Health Medicine with senior leadership roles across academia, government, and global health advisory. He is a Visiting Senior Research Fellow at the Saw Swee Hock School of Public Health, National University of Singapore, and holds parallel appointments at University College London (UCL) and the UK Health Security Agency (UKHSA). At UKHSA, he supports national strategy and policy for Immunisation & Vaccine Preventable Diseases.
As Co-Director of Aceso Global Health Consultants, Dr. Manikam provided technical leadership for the £20 million ASEAN–UK Health Security Partnership. He led the independent panel review of program proposals across all 10 ASEAN Member States and Timor-Leste, overseeing technical evaluation and investment prioritization to strengthen regional pandemic preparedness.
His commercial expertise includes advising Ensilitech, a biotechnology firm that secured £4.5 million to scale next-generation vaccine stabilization technologies. Previously, he was a NICE Scholar and an Academic Clinical Lecturer at the Chatham House Centre for Global Health Security. He also founded the Childhood Infection and Pollution (CHIP) Consortium, a multi-country initiative addressing antimicrobial resistance and childhood infections in underserved urban communities through "One Health" and citizen science approaches.
Dr. Manikam’s unique strength lies in his ability to bridge the gap between complex biotechnological innovation and large-scale pharmaceutical implementation, ensuring that cutting-edge medical advancements are strategically aligned with global regulatory frameworks and public health delivery systems.
Chyntia Aryanti Mayadewi, MSc (Nut)
Chyntia Aryanti Mayadewi is a public health consultant and researcher specializing in digital health transformation, infectious disease emergency response, and community nutrition. She currently serves as a Senior Analyst at the Health Technology Transformation and Digitalization Team of the Indonesian Ministry of Health, where she leads initiatives to implement digital solutions for primary healthcare, particularly in resource-limited settings.
Her voluntary experience includes her role as mentor for master student at Centre for Infectious Disease Emergency Response (CIDER), NUS Yong Loo Lin School of Medicine. During the COVID-19 pandemic, she was a key figure in the Indonesia One Health University Network (INDOHUN), delivering critical training for contact tracers and co-writing comparative policy analysis of Indonesia-South Korea COVID-19 pandemic management.
In the private and consultancy sectors, Chyntia is a Consultant for Aceso Global Health Consultants (Singapore). In this capacity, she has led multi-sectoral fieldwork for the Childhood Infection and Pollution (CHIP) consortium, collaborating with academic institutions in the UK, US, and Hong Kong to address health challenges in urban slum areas through a "One Health" approach.
She holds a Master’s degree in Community Nutrition from Universitas Indonesia and has published extensively on health information systems (HIS), nutrition surveillance, and pandemic response in peer-reviewed journals such as JMIR Medical Informatics and Frontiers in Public Health.
Prof Shamez Ladhani
Prof Shamez Ladhani PhD MRCPCH(UK) MSc(distinction) MBBS(hons) BSc(hons) is a paediatric infectious diseases consultant at St. George's Hospital, professor of paediatric infectious diseases and vaccinology at City St. George's University of London (CSG) and consultant epidemiologist at UK Health Security Agency (UKHSA). He completed his medical training at Guy's and St. Thomas's Hospitals, London, and then worked in a children's hospital in rural Kenya. Upon returning to London, he obtained his PhD in genetic epidemiology and vaccine failure in children and completed his specialist paediatric infectious diseases training at St. George's and Great Ormond Street Hospitals, London.
At the UKHSA, he is the clinical lead for a number of national vaccine preventable infections, including Haemophilus influenzae, Streptococcus pneumoniae and Neisseria meningitidis, which are all major causes of childhood bacterial meningitis. He has led the national implementation and evaluation of new vaccines and optimised national immunisation schedules to provide maximum public health benefit.
During the COVID-19 pandemic, he was the clinical lead for SARS-CoV-2 surveillance in Children at UKHSA. His work has focused on national surveillance of SARS-CoV-2, PIMS-TS and long COVID, immune responses to SARS-CoV-2 in children compared to adults as well as infection, transmission and outbreaks in educational settings and COVID-19 vaccines for children.
At CSG, he has undertaken vaccine trials in infants, children, adolescents, adults and pregnant women to support licensure of new vaccines as well as optimising immunisation schedules for licensed vaccines to inform national immunisation policy.
He has published extensively in the field of paediatric infectious diseases and vaccine-preventable infections, with more than 500 publications in peer-reviewed journal, including the New England Journal of Medicine, Journal of the American Medical Association, British Medical Journal, the Lancet journals and Nature journals. Beyond academia, his clinical trials and real-world evidence have been fundamental in securing the licensure of next-generation vaccines. By bridging the gap between clinical research and pharmaceutical regulation, he ensures that life-saving immunizations are both safe and accessible for global populations.